Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.) Patents (Class 424/94.61)
  • Patent number: 10533208
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 14, 2020
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Ida Annunziata, Alessandra D'Azzo
  • Patent number: 10501730
    Abstract: Variants of mannanase, compositions including the variants, to methods for their production and to methods of using the variants to degrade and modify mannan containing material.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 10, 2019
    Assignee: AB ENZYMES OY
    Inventors: Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Terhi Puranen
  • Patent number: 10358636
    Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: July 23, 2019
    Assignees: STEALTH BIOLOGICS, LLC, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Karl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
  • Patent number: 10357542
    Abstract: The present invention provides composition and methods for diagnosis and treatment of lysosomal storage diseases and their diagnosis and treatment, including Gaucher's Disease and Tay-Sachs disease, and particularly which utilize progranulin (PGRN), or active PGRN peptides, including atsttrin. The invention also provides animal models of lysosomal storage diseases, including Gaucher's Disease and Tay-Sachs disease, based on or including PGRN mutations including PGRN null mutants and PGRN gene knock outs.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 23, 2019
    Assignee: New York University
    Inventors: Chuanju Liu, Jinlong Jian
  • Patent number: 10328128
    Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 25, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald B. Moss
  • Patent number: 10301629
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 28, 2019
    Assignee: PORTAGE PHARMACEUTICALS LTD.
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10301374
    Abstract: A method of producing collagen from hydrolyzed egg membrane includes combining 95% ethanol, cold water, a bacterial pH neutral protease and/or an alkaline bacterial protease, a pH neutral bacterial metalloendopeptidase, sodium bisulfite, and egg membrane. Once combined, the solution is mixed slowly and then heated to a desired pH range and temperature. Once a desired temperature is reached, the heated solution is set aside to digest for a prolonged period of time. Next, the digested solution is centrifuged and collected to form a filtered solution. Finally, the filtered solution is spray dried and packaged.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: May 28, 2019
    Inventor: Robert den Hoed
  • Patent number: 10251873
    Abstract: Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing ?-galactosidase A activity in the patient.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 9, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10239798
    Abstract: Disclosed are methods of enhancing plant growth, comprising treating seed at least one month prior to planting with an effective amount of a plant signal molecule, wherein upon harvesting the plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to plants harvested from untreated seed, or compared to plants harvested from seed treated with the signal molecule just prior to or within a week or less of planting.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 26, 2019
    Assignee: NOVOZYMES BIOAG A/S
    Inventors: R. Stewart Smith, Ahsan Habib, John Kosanke
  • Patent number: 10208299
    Abstract: Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Russell Gotschall, Hung V. Do
  • Patent number: 10206396
    Abstract: Disclosed are methods of enhancing plant growth, comprising treating plant seed or the plant that germinates from the seed with an effective amount of at least one chitooligosaccharide, wherein upon harvesting the plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to untreated plants or plants harvested from untreated seed.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: February 19, 2019
    Assignee: NOVOZYMES BIOAG A/S
    Inventors: R. Stewart Smith, Ahsan Habib
  • Patent number: 10167462
    Abstract: The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 1, 2019
    Assignee: LYSANDO AG
    Inventor: Irina Anosova
  • Patent number: 10160976
    Abstract: Disclosed herein is the nucleotide sequence of the Chromobacterium subtsugae genome. Also provided are the nucleotide sequences of open reading frames in the C. subtsugae genome (i.e., C. subtsugae genes). In addition, the amino acid sequences of proteins encoded by the C. subtsugae genome are provided. Nucleic acids, vectors and polypeptides comprising the aforementioned sequences are also provided. Homologues, functional fragments and conservative variants of the aforementioned sequences are also provided. Compositions having pesticidal, bioremedial and plant growth-promoting activities comprising C. subtsugae genes and proteins, and methods for the use of these compositions, are also provided.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: December 25, 2018
    Assignee: Marrone Bio Innovations, Inc.
    Inventors: Ana Lucia Cordova-Kreylos, Debora Wilk, Pamela Marrone
  • Patent number: 10137176
    Abstract: A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: The Trustee of the University of Pennsylvania
    Inventors: James M. Wilson, Brittney L. Gurda
  • Patent number: 10125228
    Abstract: Provided herein is a thermoplastic elastomer hydrogel and methods of making such. The hydrogel comprises a glass formed from poly(styrene)-b-poly(ethylene oxide) in which the coronal chain end has been functionalized with photodimerizable groups (AB-photo) and a liquid medium at a concentration between about 32:1 and about 2:1 liquid medium/AB-photo by weight. The hydrogel has a fatigue resistance to at least 500,000 compression cycles.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 13, 2018
    Assignee: Colorado State University Research Foundation
    Inventors: Travis S. Bailey, Nabila Asem Huq, Vincent F. Scalfani, John R. Ekblad, Alexander T. Leonard
  • Patent number: 10124126
    Abstract: A system and methods for the delivery of oxygen through a body cavity of a subject using oxygen microbubbles. Through circulation of oxygen microbubbles through the body cavity, oxygen and carbon dioxide exchange may occur. Overall improvement in extending survival rate time during emergency situations caused by pulmonary or similar oxygen-intake restricting injury and/or failure may be achieved through use of the invented system and methods.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 13, 2018
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Mark A. Borden, Benjamin S. Terry
  • Patent number: 10117830
    Abstract: A stable pharmaceutical composition that includes an active agent selected from 1-deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. Pompe disease is an example of a lysosomal storage disorder. Pompe disease is caused by a deficiency in the enzyme acid alpha-glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 6, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hing Char, Sergey Tesler, Jiping Yang, Enrique Dilone
  • Patent number: 10106837
    Abstract: This invention provides a single process that collects any and all target nucleic acids from a sample that can contain any of a number of biological species, including bacteria, viruses, or fungi, where the first step renders the sample nonhazardous and releases nucleic acids from cell structures, compartments, and molecular complexes that may hold them, the second step concentrates the target nucleic acids from even very highly dilute states, in the third step releases these in a form that, following dilution, makes them compatible with processes that amplify nucleic acids, both standard PCR as well as isothermal amplification protocols. The pre-amplification process involves ammonia solutions no more toxic than those found in the commercial product Windex, requires no electrical power, requires materials no more complex than water desalinization resin and salt, and can be used by inexperienced individuals.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: October 23, 2018
    Inventor: Steven A Benner
  • Patent number: 10059973
    Abstract: The invention provides novel carbohydrate esters, in particular disaccharide esters, and the methods of their preparation. These compounds find use as microbial media components for the induction of gene expression in microbial fermentation processes.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: August 28, 2018
    Assignee: QINGDAO VLAND BIOTECH GROUP CO., LTD.
    Inventor: Tom Tao Huang
  • Patent number: 10047351
    Abstract: The disclosure provides a polypeptide with a mutation having cellobiohydrolase activity and improved thermal stability.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 14, 2018
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Kazuhiko Ishikawa, Seiichiro Kishishita, Makoto Nakabayashi, Saori Kamachi, Toshiaki Yanamoto, Tatsuya Fujii
  • Patent number: 10017581
    Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating Pompe disease.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 10, 2018
    Assignee: Valerion Therapeutics, LLC
    Inventors: Dustin D. Armstrong, Jeffrey C. Way
  • Patent number: 10006038
    Abstract: Methods for consolidated pretreatment and hydrolysis of genetically engineered plants expressing cell wall degrading enzymes are provided. Expression cassettes and vectors for making transgenic plants are described. Plants engineered to express one or more cell wall degrading enzymes using expression cassettes and vectors of the invention are also provided.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 26, 2018
    Assignee: AGRIVIDA, INC.
    Inventors: R. Michael Raab, Dongcheng Zhang, Oleg Bougri
  • Patent number: 9981021
    Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 29, 2018
    Assignee: KINETIQ, INC.
    Inventors: Mingju Cao, Alexander M. Cao
  • Patent number: 9909101
    Abstract: Provided herein are methods of perfusion culturing an adherent mammalian cell using a shake flask and a plurality of microcarriers, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 6, 2018
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang, Jennifer Tengtrakool, Weichang Zhou
  • Patent number: 9840727
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 12, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
  • Patent number: 9827189
    Abstract: A stable pharmaceutical composition that includes an active agent selected from 1-deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. Pompe disease is an example of a lysosomal storage disorder. Pompe disease is caused by a deficiency in the enzyme acid alpha-glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 28, 2017
    Assignee: Amicus Therapeautics, Inc.
    Inventors: Hing Char, Sergey Tesler, Jiping Yang, Enrique Dilone
  • Patent number: 9770493
    Abstract: The present disclosure relates to a composition, and method thereof, which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 26, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Cinderella Christina Gerhardt, Luppo Edens
  • Patent number: 9770410
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: September 26, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
  • Patent number: 9752135
    Abstract: A thermostable ?-glucosidase including a ?-glucosidase catalytic domain, the ?-glucosidase catalytic domain including: (A) a polypeptide including an amino acid sequence represented by SEQ ID NO: 1; (B) a polypeptide including an amino acid sequence in which at least one amino acid is deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 1, and having hydrolytic activity using p-nitrophenyl-?-D-glucopyranoside as a substrate at least under conditions of a temperature of 75° C. and a pH of 7; or (C) a polypeptide including an amino acid sequence having at least 90% sequence identity with the amino acid sequence represented by SEQ ID NO: 1, and having hydrolytic activity using p-nitrophenyl-?-D-glucopyranoside as a substrate at least under conditions of a temperature of 75° C. and a pH of 7.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: September 5, 2017
    Assignee: Honda Motor Co., Ltd.
    Inventors: Yoshitsugu Hirose, Takahiro Gunji, Asuka Yamaguchi, Migiwa Suda, Jiro Okuma, Yasuhiro Kondo, Tomohiko Kato, Daisuke Shibata
  • Patent number: 9623090
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 18, 2017
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Eric Crombez, Kiran Bhirangi, Gabriel Martin Cohn
  • Patent number: 9580735
    Abstract: A saccharifying enzyme composition, by which excellent saccharification performance can be attained even with a low usage thereof, as well as a method for producing a saccharified solution using the same are provided. The saccharifying enzyme composition subjects lignocellulose-based biomass as a substrate to a saccharification treatment. The saccharifying enzyme composition comprises an endoglucanase not containing a cellulose-binding domain, a cellobiohydrolase containing a cellulose-binding domain, and a ?-glucosidase containing a cellulose-binding domain.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: February 28, 2017
    Assignee: HONDA MOTOR CO., LTD.
    Inventors: Maiko Fukuura, Shigenobu Mitsuzawa, Migiwa Takeda, Takeshi Ara, Daisuke Shibata
  • Patent number: 9551019
    Abstract: The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), nucleic acids encoding these proteins as well as corresponding vectors and host cells. In addition, the present invention is directed to the use of said proteins, nucleic acids, vectors and host cells for preparing medicaments. Furthermore, the present invention provides methods for producing said proteins.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 24, 2017
    Assignee: ETH ZÜRICH
    Inventors: Markus Aebi, Michael Kowarik, Umesh Ahuja
  • Patent number: 9493751
    Abstract: Described herein is a fusion polypeptide that contains (a) a first segment containing a Fibrobacter succinogenes 1,3-1,4-?-D-glucanase (Fs?-glucanase) or a fragment thereof; (b) a second segment containing a first Thermotoga maritima 1,3-?-D-glucanase (TmLam) or a fragment thereof; and (c) an optional third segment containing a second Thermotoga maritima 1,3-?-D-glucanase (TmLam) or a fragment thereof; wherein the fusion polypeptide has a glucanase activity. Also described are a nucleic acid molecule encoding the fusion polypeptide and a method of using the polypeptide.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 15, 2016
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Wei-Chun Liu
  • Patent number: 9469847
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 18, 2016
    Assignee: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Patent number: 9456602
    Abstract: A hand sanitizer composition that provides effective skin sanitization and exhibits low flammability, while containing sufficient humectant for moisturization of the skin includes an alcohol selected from the group consisting of alcohol(s) containing 4 to 6 carbon atoms in an amount of from about 10% to about 60% by volume, and one or more humectants present in an amount of from about 10% to about 80% by volume.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: October 4, 2016
    Assignee: Working Bugs, LLC
    Inventors: Cordell DeMattei, Dianne Holman, Peter K. Rossman, Thomas A. Auchtung
  • Patent number: 9452140
    Abstract: Disclosed are a composition of a vegetable soft capsule having excellent elasticity and an excellent adhesive property, provided in the form of a thin film, and having improved productivity and disintegration, and a method of preparing the same. Based on 35.3 weight part of the starch and the carrageenan, 7 weight part of the starch and 3 weight part of carrageenan are provided. In 35.3 weight part of the starch and the carrageenan, the starch contains 17.65 weight part of corn starch, 3.53 weight part of tapioca starch, and 3.53 weight part of potato starch are provided based on the weight ratio, and the carrageenan contains 7.592 weight part of iota carrageenan, 2.118 weight part of kappa carrageenan, 0.8 weight part of baking soda (sodium bicarbonate), 0.04 weigh part of arabic gum, and 0.04 weight part of Levan. Together with 35.3 weight part of the starch and the carrageenan, 17.7 weight part of glycerin, and 47 weight part of purified water are composited.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: September 27, 2016
    Assignee: Chang Sung Softgel System Ltd
    Inventor: Ju-su Kim
  • Patent number: 9453847
    Abstract: Described herein are isolated nucleic acid molecules comprising nucleotide sequence encoding mannose receptor, C type 1 (MRC1) wherein the 5? region of the nucleotide sequence encoding MRC1 is codon optimized; cells comprising such nucleic acid molecules; and methods of detecting antibody production, e.g., neutralizing antibody production, in a subject being treated for Gaucher disease using such cells.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: September 27, 2016
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Juan Ruiz, Marcia Sellos-Moura, Michael F. Concino, Pan Luying, Paolo Martini, Bettina Strack-Logue, Scott Alderucci
  • Patent number: 9404100
    Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 2, 2016
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Kenneth Joseph Valenzano, John Crowley, Richie Khanna, John Flanagan
  • Patent number: 9402886
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 2, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Hunter
  • Patent number: 9320711
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: April 26, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Farah Natoli, Gaozhong Zhu, Jennifer Terew, Yuan Jiang, Jamie Tsung, Zahra Shahrokh, Brian Vernaglia, Jing Pan, Richard Pfeifer, Pericles Calias
  • Patent number: 9315544
    Abstract: A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: April 19, 2016
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Lin-Shien Fu, Shun-Lung Fang
  • Patent number: 9309538
    Abstract: The present invention relates to the expression and optimization of enzymes involved in lignocellulosic biomass decomposition. The present invention relates more particularly to beta-glucosidase variants comprising at least one modification among the amino acids located at positions 225, 238, 240 and 241, according to the numbering in SEQ ID No. 2 of Trichoderma reesei beta-glucosidase, and also relates to the use of said variants having improved effectiveness in methods for cellulose decomposition and biofuel production.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: April 12, 2016
    Assignees: IFP Energies Nouvelles, PROTEUS
    Inventors: Nicolas Lopes-Ferreira, Antoine Margeot, Hugues Mathis, Laurent Fourage
  • Patent number: 9283181
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: March 15, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Patent number: 9265735
    Abstract: Methods for treating Alzheimer's Disease (AD) using modulators of lysosomal activity are described herein. More particularly, methods described herein relate to the use and application of compounds or agents that enhance lysosomal activity for the treatment of AD. In a particular aspect, the method relates to the use and application of compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD. Also described herein are methods and assays for screening to identify compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: February 23, 2016
    Assignees: New York University, The Research Foundation for Mental Hygiene, Inc.
    Inventors: Ralph A. Nixon, Ju-Hyun Lee, Devin Wolfe
  • Patent number: 9249399
    Abstract: This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 2, 2016
    Assignee: Oxyrane UK Limited
    Inventors: Wouter Vervecken, Kathleen Camilla Telesphore Alida Maria Piens, Jan Robert Ludo Stout, Gwenda Noëlla Pynaert
  • Patent number: 9220677
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: December 29, 2015
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Rick Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
  • Patent number: 9206457
    Abstract: The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 8, 2015
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Hung V. Do
  • Patent number: 9198957
    Abstract: G. vaginalis infection, a major cause of bacterial vaginosis (BV), is associated with biofilm formation. The present invention relates to treatment of G. vaginalis infections and BV with DNase. DNase reduces biofilm formation and increases biofilm breakdown, both in a dose dependent manner. The present invention further relates to treating BV and G. vaginalis infections with a combination of DNase and an antibiotic known to treat these diseases.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: December 1, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Adam J. Ratner, Saul Hymes
  • Patent number: 9193964
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: November 24, 2015
    Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIES
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • Patent number: 9185921
    Abstract: A method for making a milk product (e.g. a yogurt) comprising adding an effective amount of an N-linked glycosidase and/or an O-linked glycosidase to milk.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: November 17, 2015
    Assignee: Chr. Hansen A/S
    Inventors: Jonas Jacobsen, Sandra Lykke Wind, Karsten Bruun Qvist